Helicobacter pylori and Its Association with Anemia

Infection with *Helicobacter pylori* represents one of the most prevalent bacterial colonizations in humans, affecting nearly half of the global population. While many individuals remain asymptomatic carriers, a subset of patients may develop severe gastrointestinal pathologies, including **gastric and duodenal ulcers**, and in extreme cases, **gastric adenocarcinoma**. Emerging clinical evidence further underscores a significant correlation between chronic *H. pylori* infection and extrapgastrointestinal complications, most notably **iron-deficiency anemia (IDA)**. This association arises from two primary mechanisms: **impaired intestinal iron absorption** due to bacterial-induced mucosal damage and **chronic inflammation**, which disrupts systemic iron metabolism. Consequently, in confirmed cases of *H. pylori* infection, **pathogen eradication** alone is insufficient; it must be complemented by **targeted iron supplementation** using highly bioavailable formulations and **dietary modifications** to enhance intake of both heme and non-heme iron sources. Anemia itself is a heterogenous disorder with multiple etiologies, encompassing **deficiency-related anemia** (stemming from iron, vitamin B12, or folate insufficiency), **aplastic anemia** (caused by bone marrow failure), **hemolytic anemia** (characterized by accelerated erythrocyte destruction), and **posthemorrhagic anemia** (following acute or chronic blood loss). **Pregnant women** constitute a high-risk group due to elevated iron requirements, where deficiency can lead to adverse maternal and fetal outcomes. Therefore, **comprehensive laboratory assessment**—including complete blood count, ferritin levels, transferrin saturation, and fecal occult blood testing—should be routinely performed in patients suspected of anemia, particularly those with concurrent *H. pylori* infection or symptoms such as persistent fatigue, pallor, dizziness, or brittle nails.